SC
CPXX

Steven Cohen’s CELATOR PHARMACEUTICALS INC. COMMON STOCK CPXX Stock Holding History

Steven Cohen’s Portfolio CPXX Stock Details CPXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-19,900
Closed -$219K – 968
2016
Q1 		$219K Buy
+19,900
New +$65.2K ﹤0.01% 680

Other funds holding CPXX

CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $15.7B AUM 36.4% 1-Year Est. Return

Steven Cohen's CPXX Position: Q2 2016 in Review

Steven Cohen sold out of CELATOR PHARMACEUTICALS INC. COMMON STOCK (CPXX) in Q2 2016, closing a stake of 19,900 shares — an estimated $219K sold.

Steven Cohen first reported a position in CPXX in Q1 2016 and held it in 1 quarter. The position peaked at $219K in Q1 2016. 119 funds tracked by Wall St. Rank hold CPXX as of Q2 2016.

  • Steven Cohen reported no remaining CELATOR PHARMACEUTICALS INC. COMMON STOCK position as of Q2 2016 after selling out during the quarter.
  • Steven Cohen sold 19,900 CELATOR PHARMACEUTICALS INC. COMMON STOCK shares in Q2 2016, an estimated $219K.
  • Steven Cohen first reported a position in CELATOR PHARMACEUTICALS INC. COMMON STOCK in Q1 2016 and held it in 1 quarter.
  • Steven Cohen's CELATOR PHARMACEUTICALS INC. COMMON STOCK position peaked at $219K in Q1 2016.
  • 119 funds tracked by Wall St. Rank held CELATOR PHARMACEUTICALS INC. COMMON STOCK as of Q2 2016.

Based on Point72 Asset Management's 13F filing for Q2 2016, filed 15 Aug 2016.